Fed. Cir.

UCB, Inc. v. Annora Pharma Private Limited, No. 24-1056 (Fed. Cir. Nov. 21, 2023)

General / Procedural

Court: U.S. Court of Appeals for the Federal Circuit
Case No.: No. 24-1056
Decided: November 21, 2023
Judge: See opinion
Document: Nonprecedential Opinion
Length: 2 pages

Full Text Analysis Cite this Opinion

Download Opinion (PDF)

NOTE: This order is nonprecedential. United States Court of Appeals

for the Federal Circuit UCB, INC., UCB BIOPHARMA SRL,

Plaintiffs-Appellees

ANNORA PHARMA PRIVATE LIMITED,

APOTEX INC., APOTEX CORP.,

Defendants

MSN PHARMACEUTICALS, INC., MSN

LABORATORIES PRIVATE LTD.,

Defendants-Appellants

2024-1056

Appeal from the United States District Court for the District of Delaware in No. 1:20-cv-00987-CFC-JLH, 1:20-cv-01343-CFC, Chief Judge Colm F. Connolly.

O R D E R

The parties having so agreed, it is ordered that: (1) The proceeding is DISMISSED under Fed. R. App. P. 42 (b).

22 UCB, INC. V. ANNORA PHARMA PRIVATE LIMITED

(2) Each side shall bear their own costs.

FOR THE COURT November 21, 2023

Date /s/ Jarrett B. Perlow

Jarrett B. Perlow Clerk of Court

ISSUED AS A MANDATE: November 21, 2023

Text extracted from the official PDF and reflowed for reading. It is not a certified transcript — the PDF linked above is the authoritative document.

Analysis is coming soon.

A plain-English account of the issues, facts and holding, written by Patent Case Watch. The opinion itself — its full text, its PDF and everything else on this page — stays free to read for everyone, always.

Cite this opinion

UCB, Inc. v. Annora Pharma Private Limited, No. 24-1056 (Fed. Cir. Nov. 21, 2023).

Record ID: CAFC-24-1056-20231121
Permalink: https://patentcasewatch.com/opinions/CAFC-24-1056-20231121

No reporter citation is shown because the official source does not supply one; none is inferred here. Check the opinion and a citator before relying on this form.

Source: Federal Circuit opinions and orders · retrieved August 15, 2026 · Report an error